Related Experiment Videos
[Treatment of bilharziasis]
1Institut de médecine et d'épidémiologie africaines (Fondation Léon Mba), Paris.
La Revue Du Praticien
|February 15, 1993
Summary
Praziquantel simplifies bilharziosis treatment but faces availability issues in endemic regions. Early intervention and mass chemoprophylaxis are crucial, with economic considerations favoring oxamniquine or niridazole-metrifonate combinations.
Area of Science:
- Parasitology
- Tropical Medicine
- Pharmacology
Context:
- Bilharziosis (schistosomiasis) poses a significant public health challenge in endemic areas.
- Praziquantel is the primary drug for treating bilharziosis, but its accessibility is limited.
- Severe sequelae necessitate early diagnosis and treatment to prevent long-term complications.
Purpose:
- To discuss the challenges and strategies for effective bilharziosis treatment and control.
- To highlight the importance of praziquantel availability and early intervention.
- To explore alternative and combination therapies for mass chemoprophylaxis.
Summary:
- Praziquantel offers effective bilharziosis treatment but is often unavailable in regions where it is most needed.
- Early treatment is critical to prevent severe, irreversible health consequences.
- Mass chemoprophylaxis is essential, with praziquantel being the preferred agent, though economic factors may necessitate the use of oxamniquine or a niridazole-metrifonate combination.
Impact:
- Improved strategies for praziquantel distribution are needed to enhance treatment accessibility.
- Focus on early detection and treatment can reduce the burden of severe bilharziosis sequelae.
- Economic considerations play a vital role in selecting appropriate mass chemoprophylaxis regimens in resource-limited settings.